$15.90▼-0.18 (-1.12%)
After Hours:$15.82-0.08 (-0.50%)
Ultragenyx Pharmaceutical Inc. (RARE)
R&D to Revenue
111.44%
Fiscal year · Period ending:

RARE R&D to Revenue
Latest reported111.44%period ending
Latest reported111.44%period ending
RARE FY R&D/Revenue (0.00% → 111.44%)
Latest values, visible window
High-resolution chart · PNG
What is r&d to revenue?
R&D spending as percentage of revenue.
RARE r&d to revenue history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 111.4413% | |
| 124.5676% | |
| 149.3265% | |
| 194.2562% | |
| 141.4754% | |
| 152.0437% | |
| 344.5581% | |
| 570.9253% | |
| 8,868.4533% | |
| 137,747.3684% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% |
Explore More
RARE Financial Metrics
Explore 130+ historical metrics & ratios
Stock Comparison
Compare equities side by side
52-Week Highs Breakout
Stocks breaking to new annual highs
52-Week Lows Oversold
S&P 500 oversold value screener
Trending Momentum
Relative strength momentum leaders
Earnings Calendar
Upcoming earnings dates & reports
S&P 500 Screener
Filter and sort all 500 stocks
Market Movers
Today's biggest gainers and losers
Market Heatmap
Visual sector performance